PE20000559A1 - Formulacion de tabletas comprimidas de efavirenz - Google Patents
Formulacion de tabletas comprimidas de efavirenzInfo
- Publication number
- PE20000559A1 PE20000559A1 PE1999000431A PE00043199A PE20000559A1 PE 20000559 A1 PE20000559 A1 PE 20000559A1 PE 1999000431 A PE1999000431 A PE 1999000431A PE 00043199 A PE00043199 A PE 00043199A PE 20000559 A1 PE20000559 A1 PE 20000559A1
- Authority
- PE
- Peru
- Prior art keywords
- efavirenz
- formulation
- compressed tablets
- aids
- inhibitor
- Prior art date
Links
- XPOQHMRABVBWPR-UHFFFAOYSA-N Efavirenz Natural products O1C(=O)NC2=CC=C(Cl)C=C2C1(C(F)(F)F)C#CC1CC1 XPOQHMRABVBWPR-UHFFFAOYSA-N 0.000 title abstract 3
- XPOQHMRABVBWPR-ZDUSSCGKSA-N efavirenz Chemical compound C([C@]1(C2=CC(Cl)=CC=C2NC(=O)O1)C(F)(F)F)#CC1CC1 XPOQHMRABVBWPR-ZDUSSCGKSA-N 0.000 title abstract 3
- 229960003804 efavirenz Drugs 0.000 title abstract 3
- 239000007891 compressed tablet Substances 0.000 title abstract 2
- 238000009472 formulation Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 208000030507 AIDS Diseases 0.000 abstract 1
- 208000031886 HIV Infections Diseases 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000002777 nucleoside Substances 0.000 abstract 1
- 150000003833 nucleoside derivatives Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- AIDS & HIV (AREA)
- Biophysics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
SE REFIERE A UNA FORMULACION DE TABLETAS COMPRIMIDAS QUE COMPRENDE a)50% EN PESO DE EFAVIRENZ, b)COMPONENTE DE CARGA TAL COMO LACTOSA, CARBONATO DE CALCIO, SULFATO DE CALCIO, ENTRE OTROS; c)DESINTEGRANTE Y SUPERDESINTEGRANTE TALES COMO ACIDO ALGINICO, CARBOXIMETILCELULOSA SODICA, DIOXIDO DE SILICIO COLOIDAL, CROSCARMELOSA, ENTRE OTROS; d)AGLUTINANTE TAL COMO ACACIA, ACIDO ALGINICO, CARBOMERO, HIDROXIPROPILCELULOSA, ENTRE OTROS; e)SURFACTANTE TAL COMO DOCUSATO DE SODIO, CLORURO DE BENZALCONIO, CLORURO DE BENCETONIO Y CETRIMIDA f)COMPONENTE DE CARGA/COADYUVANTE DE COMPRESION TAL COMO CARBONATO DE CALCIO, SULFATO DE CALCIO, AZUCARES COMPRESIBLES, LACTOSA HIDRATADA SECADA POR ATOMIZACION, ENTRE OTROS; g)LUBRICANTE TAL COMO ESTEARATO DE CALCIO, MONOESTEARATO DE GLICERILO, PALMITOESTEARATO DE GLICERILO, ACEITE DE RICINO MINERAL, ENTRE OTROS Y i)SOLVENTE TAL COMO AGUA, ETANOL. UNA COMPOSICION PREFERIDA CONTIENE 300mg DE EFAVIRENZ, 120mg DE CELULOSA MICROCRISTALINA, 19,2mg DE HIDROXIPROPILCELULOSA, 30mg DE CROSCARMELOSA SODICA, 6mg DE SULFATO LAURICO Y SODIO, 118,8mg DE LACTOSA HIDRATADA SECADA POR ATOMIZACION, 6mg DE ESTEARATO DE MAGNESIO. TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION. EL EFAVIRENZ ES UN INHIBIDOR DE TRANSCRIPTASA INVERSA NO NUCLEOSIDO Y PUEDE SER UTIL PARA EL TRATAMIENTO DE INFECCIONES POR VIH Y SIDA
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8692198P | 1998-05-27 | 1998-05-27 | |
| GBGB9815800.9A GB9815800D0 (en) | 1998-07-21 | 1998-07-21 | Compressed tablet formulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20000559A1 true PE20000559A1 (es) | 2000-07-05 |
Family
ID=26314071
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE1999000431A PE20000559A1 (es) | 1998-05-27 | 1999-05-21 | Formulacion de tabletas comprimidas de efavirenz |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP1083901B1 (es) |
| JP (1) | JP4000354B2 (es) |
| AT (1) | ATE237332T1 (es) |
| AU (1) | AU761182B2 (es) |
| CA (1) | CA2332876C (es) |
| CO (1) | CO5070643A1 (es) |
| CY (1) | CY1113191T1 (es) |
| DE (1) | DE69906963D1 (es) |
| DK (1) | DK1332757T3 (es) |
| ES (1) | ES2388849T3 (es) |
| PE (1) | PE20000559A1 (es) |
| PT (1) | PT1332757E (es) |
| SI (1) | SI1332757T1 (es) |
| WO (1) | WO1999061026A1 (es) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA72207C2 (uk) | 1998-04-07 | 2005-02-15 | Брістол- Майєрс Сквібб Фарма Компані | Фармацевтична композиція ефавіренцу з добавкою дезінтегруючих агентів у вигляді швидкорозчинних капсул або таблеток та спосіб її виготовлення |
| CA2311734C (en) * | 2000-04-12 | 2011-03-08 | Bristol-Myers Squibb Company | Flash-melt oral dosage formulation |
| US20030124186A1 (en) * | 2001-11-27 | 2003-07-03 | Hussain Munir A. | Efavirenz tablet formulation having unique biopharmaceutical characteristics |
| US7396855B2 (en) | 2002-07-24 | 2008-07-08 | Children's Hospital Medical Center | Compositions and products containing S-equol, and methods for their making |
| AU2004206821C1 (en) | 2003-01-14 | 2009-10-01 | Gilead Sciences, Inc. | Compositions and methods for combination antiviral therapy |
| US7198653B2 (en) * | 2003-07-31 | 2007-04-03 | Delavau Llc | Calcium carbonate granulation |
| JP2005089396A (ja) * | 2003-09-19 | 2005-04-07 | Pola Chem Ind Inc | イソフラボン含有経口投与組成物 |
| TWI375560B (en) | 2005-06-13 | 2012-11-01 | Gilead Sciences Inc | Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same |
| TWI471145B (zh) | 2005-06-13 | 2015-02-01 | Bristol Myers Squibb & Gilead Sciences Llc | 單一式藥學劑量型 |
| WO2007052289A2 (en) * | 2005-07-22 | 2007-05-10 | Rubicon Research Pvt Ltd. | Novel dispersible tablet composition |
| WO2007013047A2 (en) * | 2005-07-29 | 2007-02-01 | Ranbaxy Laboratories Limited | Water-dispersible anti-retroviral pharmaceutical compositions |
| UA95093C2 (uk) * | 2005-12-07 | 2011-07-11 | Нікомед Фарма Ас | Спосіб одержання кальцієвмісної сполуки |
| US20090088424A1 (en) * | 2007-08-17 | 2009-04-02 | Ilan Zalit | Methods and compositions for controlling the bioavailability of poorly soluble drugs |
| DE102008047910A1 (de) | 2008-09-19 | 2010-03-25 | Molkerei Meggle Wasserburg Gmbh & Co. Kg | Tablettierhilfsstoff auf Laktose- und Cellulosebasis |
| US20110009347A1 (en) | 2009-07-08 | 2011-01-13 | Yin Liang | Combination therapy for the treatment of diabetes |
| WO2011131943A2 (en) | 2010-04-20 | 2011-10-27 | Cipla Limited | Pharmaceutical compositions |
| ES2596291T3 (es) | 2010-05-11 | 2017-01-05 | Janssen Pharmaceutica, N.V. | Formulaciones farmacéuticas que comprenden derivados de 1-(beta-d-glucopiranosil)-2-tienilmetilbenceno como inhibidores de sglt |
| EP2447255A1 (en) | 2010-10-14 | 2012-05-02 | Lonza Ltd. | Process for the synthesis of cyclic carbamates |
| EP2441759A1 (en) | 2010-10-14 | 2012-04-18 | Lonza Ltd. | Process for the synthesis of cyclic carbamates |
| DK2753306T3 (da) * | 2011-10-17 | 2020-12-14 | Lexicon Pharmaceuticals Inc | Faste doseringsformer af (s)-ethyl 2-amino-3-(4-(2-amino-6-((r)-1-(4-chlor-2-(3-methyl-1h-pyrazol-1-yl)phenyl)-2,2,2-trifluorethoxy)pyrimidin-4-yl)phenyl)propanoat |
| CN103508973B (zh) * | 2012-06-25 | 2016-04-27 | 上海迪赛诺药业有限公司 | 制备依非韦伦i型结晶的方法 |
| IN2013MU03370A (es) | 2013-10-25 | 2015-09-25 | Cipla Ltd | |
| RU2759544C1 (ru) * | 2021-01-29 | 2021-11-15 | Общество с ограниченной ответственностью "АМЕДАРТ" | Твёрдая фармацевтическая композиция для изготовления перорального терапевтического средства для профилактики и/или лечения ВИЧ-инфекции |
| CN113499441A (zh) * | 2021-08-05 | 2021-10-15 | 上海合全医药有限公司 | 一种药用糖包衣液及其制备方法 |
| CN113999543B (zh) * | 2021-10-29 | 2022-11-04 | 广西华纳新材料股份有限公司 | 一种钙-硅核壳结构纳米碳酸钙的制备方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU1694295A (en) * | 1994-01-28 | 1995-08-15 | Merck & Co., Inc. | Benzoxazinones as inhibitors of hiv reverse transcriptase |
| US5633405A (en) * | 1995-05-25 | 1997-05-27 | Merck & Co., Inc. | Asymmetric synthesis of (-)-6-chloro-4-cyclopropyl-ethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxanzin-2-one |
| AU7912398A (en) * | 1997-05-17 | 1998-12-11 | Glaxo Group Limited | Antiviral combinations containing the carbocyclic nucleoside 1592u89 |
-
1999
- 1999-05-21 PE PE1999000431A patent/PE20000559A1/es not_active IP Right Cessation
- 1999-05-21 CO CO99031381A patent/CO5070643A1/es unknown
- 1999-05-24 DK DK03076054.0T patent/DK1332757T3/da active
- 1999-05-24 JP JP2000550486A patent/JP4000354B2/ja not_active Expired - Lifetime
- 1999-05-24 DE DE69906963T patent/DE69906963D1/de not_active Expired - Lifetime
- 1999-05-24 AT AT99925793T patent/ATE237332T1/de not_active IP Right Cessation
- 1999-05-24 EP EP99925793A patent/EP1083901B1/en not_active Expired - Lifetime
- 1999-05-24 WO PCT/US1999/011464 patent/WO1999061026A1/en not_active Ceased
- 1999-05-24 CA CA002332876A patent/CA2332876C/en not_active Expired - Lifetime
- 1999-05-24 PT PT03076054T patent/PT1332757E/pt unknown
- 1999-05-24 AU AU42010/99A patent/AU761182B2/en not_active Expired
- 1999-05-24 SI SI9931069T patent/SI1332757T1/sl unknown
- 1999-05-24 ES ES03076054T patent/ES2388849T3/es not_active Expired - Lifetime
-
2012
- 2012-08-29 CY CY20121100778T patent/CY1113191T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ATE237332T1 (de) | 2003-05-15 |
| CO5070643A1 (es) | 2001-08-28 |
| CY1113191T1 (el) | 2016-04-13 |
| WO1999061026A1 (en) | 1999-12-02 |
| DE69906963D1 (de) | 2003-05-22 |
| EP1083901B1 (en) | 2003-04-16 |
| SI1332757T1 (sl) | 2012-10-30 |
| AU761182B2 (en) | 2003-05-29 |
| EP1083901A1 (en) | 2001-03-21 |
| JP4000354B2 (ja) | 2007-10-31 |
| AU4201099A (en) | 1999-12-13 |
| PT1332757E (pt) | 2012-09-03 |
| ES2388849T3 (es) | 2012-10-19 |
| CA2332876A1 (en) | 1999-12-02 |
| CA2332876C (en) | 2008-07-08 |
| DK1332757T3 (da) | 2012-09-24 |
| JP2002516281A (ja) | 2002-06-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20000559A1 (es) | Formulacion de tabletas comprimidas de efavirenz | |
| BR9908438A (pt) | Tabletes de desintegração rápida | |
| MY136173A (en) | 4-oxoquinoline compound and use thereof as hiv integrase inhibitor | |
| EP1268412B8 (en) | Sulphonamido-substituted bridged bicycloalkyl derivatives | |
| DK0954314T3 (da) | Doseringsformer til bedring af mandlig erektionsdefekt | |
| MX339071B (es) | Almidon pregelatinizado en una formulacion de liberacion controlada. | |
| BG106030A (en) | Pharmaceutical composition | |
| SE9500422D0 (sv) | New oral pharmaceutical dosage forms | |
| WO2004030611A3 (en) | Non-nucleoside reverse transcriptase inhibitors | |
| HUP0102206A2 (hu) | Delavirdint tartalmazó tabletta formájú készítmény | |
| NZ507566A (en) | Formulation of fast-dissolving efavirenz capsules or tablets using super-disintegrants | |
| HU229443B1 (en) | Betha-carboline particulate form, pharmaceutical compositions containing it, their preparations and their use | |
| HUP0004544A2 (hu) | Angiotenzin-átalakító enzim inhibitora és diuretikum kombinációjának alkalmazása mikrokeringési rendellenességek kezelésére szolgáló gyógyászati készítmény előállítására | |
| DE59813162D1 (de) | Pharmazeutische zusammensetzung enthaltend clindamycin und clotrimazol, zur behandlung vaginaler infektionen | |
| IL132853A (en) | Composition for modulating the human sexual response | |
| NO960775L (no) | Anvendelse av kinoksaliner i kombinasjon med proteaseinhibitorer som legemiddel for behandling av AIDS og/eller HIV-infeksjoner | |
| CA2417935A1 (en) | Anti-inflammatory medicament | |
| HUP9901353A2 (hu) | ACE-inhibitorok alkalmazása diszpepsziás tünetek kezelésére alkalmas gyógyszerkészítmény előállítására | |
| BR0209155A (pt) | Tablete farmacêutico tendo um teor de api elevado | |
| MY121604A (en) | Combination therapy for hiv infection using the hiv protease inhibitor indinavir and the reverse transcriptase inhibitor 3tc together with azt | |
| SE0001916D0 (sv) | Novel formulation | |
| AR011707A1 (es) | Composicion farmaceutica que comprende tirosina y un alergeno opcionalmente modificado, procedimiento para su preparacion y el uso de la misma para la manufactura de un medicamento. | |
| TR199800954T2 (xx) | Y�ksek i�erikli famsiklovir tabletleri. | |
| MXPA01008587A (es) | Uso de 15-desoxiespergualina para el tratamiento de enfermedades inflamatorias hiperreactivas y enfermedades autoinmunitarias. | |
| ATE331509T1 (de) | Zusammensetzung die paracetamol und niflumic säure enthält |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| MK | Expiration of term |